State of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much

We have now had a decade of R&D directed towards improving on the applicability and activity of combinations with checkpoint inhibitors (CPIs). There have been many ups and downs, and a few surprises along the way, not the least of which is the combination value of CPIs with chemotherapy and with MTKIs, but not so much with other IO agents.  While this may be finally about to change with TIGIT, LAG3, and IL-2 programs to name a few marquee examples, questions still remain on when, where, what and how best to combine CPIs. Tis session brings together a stellar, and large, cats of experts across the BioPharma industry, from academic researchers and clinical trialists to biotechs to large pharma, to have a dialogue, maybe even a debate, on this complex and fascinating topic.


  • Jeffrey M. Bockman, PhD, EVP, Head of Oncology, Commercial BioConsulting, Lumanity


  • Jennifer Buell, PhD, President & CEO, MiNK Therapeutics
  • Michael A Curran, PhD, Associate Professor, Dept. of Immunology
  • Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
  • Björn Frendéus, PhD, CSO, BioInvent
  • Andrew Pierce, PhD, VP of Translational Biology, Crescendo Biologics Ltd
  • Peter Sandor, MD, MBA, SVP, Primary Focus Lead Immuno-oncology, Astellas
  • Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck and Co
  • Dmitriy Zamarin, MD, PhD, Translational Research Director, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center
  • Mai-Britt Zocca, PhD, CEO, IO Biotech